Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients: an Open, Single Arm, Phase II Clinical Trial

Next Previous
X
Search
Trial Profile

Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients: an Open, Single Arm, Phase II Clinical Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Envafolimab (Primary) ; Lenvatinib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms CISLD-12

    • Most Recent Events

    • 04 Jun 2024 Results assessing safety and efficacy of envafolimab plus lenvatinib combined with TACE in initially unresectable hepatocellular carcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 12 Jun 2023 Status changed from recruiting to completed.
    • 21 Jan 2023 Results(n=40) assessing Efficacy and safety of envafolimab plus lenvatinib combined with TACE in unresectable hepatocellular carcinoma presented at the 2023 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top